Shafer, Brian M.
McGee, Selina R.
Ifantides, Cristos
Williamson, Blake K.
Kannarr, Shane
Whyte, Julie
Zhang, Zuoyi
Yanke, Travis
Schachter, Scott
Funding for this research was provided by:
AbbVie
Article History
Received: 15 December 2023
Accepted: 12 March 2024
First Online: 25 April 2024
Declarations
:
: Brian M Shafer has received consulting fees, honoraria, speaker fees, and/or travel reimbursement from Alcon, Allergan (an AbbVie company), CorneaGen, Harrow Pharmaceuticals, Tarsus, and Visus Therapeutics. Selina R McGee has received consulting fees, honoraria, speaker fees, and/or travel reimbursement from Allergan (an AbbVie company), Bausch + Lomb, Bruder, Cynosure, Dompe, EyeVance, Horizon, Kala Pharmaceuticals, Lumenis, Novartis, Ocuphire, Optovue, Osmotica, Oyster Point, Sun Pharmaceutical, Tarsus, Thea, and Versant. Cristos Ifantides has received consulting fees, honoraria, speaker fees, and/or travel reimbursement from Ace Vision Group, Acufocus Inc, Alcon, Allergan (an AbbVie company), Bausch + Lomb, BVI, Centricity Vision, Hu-Med Technologies, Johnson & Johnson, New World Medical, Spect Inc, Tarsus, Trefoil, Vision 2020 USA, Visus Therapeutics, and Zeiss. Cristos Ifantides’ spouse is an employee of AbbVie and may hold AbbVie stock. Blake K Williamson has received consulting fees from Allergan (an AbbVie company), Bausch + Lomb, BVI, Glaukos, Johnson & Johnson, New World Medical, Sight Sciences, Staar, and Zeiss. Shane Kannarr has received consulting fees, honoraria, speaker fees, and/or travel reimbursements from Alcon Vision, Allergan (an AbbVie company), Bausch + Lomb, Essilor, Johnson & Johnson, Kala Pharmaceuticals, Novartis, Osmotica, Sight Sciences, Sun Pharmaceutical, Tarsus, and Vision Source. Julie Whyte is a full-time employee of Endpoint Outcomes, a Lumanity company. Zuoyi Zhang, Travis Yanke, and Scott Schachter are or were full-time employees of AbbVie and may hold AbbVie stock.
: The protocol was prospectively approved (on 17 December 2021) by the Western Copernicus Group Institutional Review Board (tracking number: 20216789) before any of the participants were contacted. The study was conducted in accordance with ethical principles of the Declaration of Helsinki and followed the guidelines of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and applicable regulatory requirements. Individuals who agreed to participate provided written informed consent before initiating the companion study.